NCT07445984

Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 250 (estimated)
• Sponsor: Azienda Ospedaliero-Universitaria di Parma · Academic / Other
• Sex: All
• Age: 1 Year
• Healthy volunteers: Not accepted

Summary

The study will be conducted retrospectively and prospectively, using bone marrow (BM) or peripheral blood (PB) samples or biopsies of lymph nodes or tissues with metastatic involvement taken from previously stored samples here at the University Hospital of Parma or taken from patients that need to underwent diagnostic evaluation for a suspect or a defined diagnosis of hematological malignancies collected at the University Hospital of Parma.

Detailed description

The hematological malignancies are referred to all the different hematological entities according to WHO 2016 Classification such as acute (AML, ALL) or chronic leukemia (CLL, CML, HCL), myeloproliferative or lymphoproliferative disorders (MF, PV, TE, CMML, NHL, HL) and myelodysplastic or myelodysplastic/myeloproliferative disorders.

Conditions

• Chronic Leukemia
• Acute Leukemia
• Myeloproliferative Disorders
• Lymphoproliferative Disorders
• Myelodysplastic Disorders

Interventions

Type	Name	Description
OTHER	Genetic, molecular and/or omics analyses	The focus of our scientific approach is based on genetic, molecular and/or omics analyses performed with new technologies (Nanostring, NGS, single cell technologies, radiomics)

Timeline

• Start date: 2021-07-28
• Primary completion: 2026-07-28
• Completion: 2026-07-28
• First posted: 2026-03-03
• Last updated: 2026-03-03

Locations

1 site across 1 country: Italy